A Study on the Efficacy and Safety of IPyC for HER2+ MBC

Fujian Medical University

Status: Completed

Conditions: Breast Cancer

Treatments: Drug: Inetetamab and Pyrotinib Combined with Chemotherapy

Study type: Observational

Funder types: Other

Identifiers

NCT06990347

K2024-534-01

Details and patient eligibility

About

Between July 2020 and August 2024, 301 HER2-positive MBC patients from five tertiary centers received the regimen until disease progression or unacceptable toxicity. Efficacy endpoints included progression-free survival (PFS), objective response rate (ORR), and clinical benefit rate (CBR).

Enrollment: 301 patients

Sex: Female

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients who underwent a biopsy of the metastatic site and were confirmed as having MBC
• patients who received inetetamab + pyrotinib + chemotherapy as metastasis therapy.

Exclusion criteria

• male patients or individuals with prior malignancy
• patients with prior or current enrollment in interventional clinical trials for MBC
• patients who received less than 2 cycles of treatment (6 weeks of inetetamab or 8 weeks of pyrotinib)
• patients who were lost to follow-up during the therapeutic process